South China Venture Capital

What South China Venture Capital does

South China Venture Capital (中南创投基金) is a privately held venture capital fund management firm founded in 2008 and headquartered in Shenzhen. The firm manages multiple RMB-denominated and USD-denominated venture capital funds and deploys capital directly into early-stage and growth-stage technology startups. Its investment focus spans three hard-tech verticals: biomedicine, semiconductors, and artificial intelligence. The firm positions itself around a mission of "capital empowering technology, technology benefiting humanity" and invests globally in technology leaders with strong scientific and commercial fundamentals, co-building value alongside scientists and entrepreneurs.

The firm's product surface is narrow by design: two primary fund vehicles, RMB and USD, that collectively back Chinese-domiciled and cross-border technology companies. Notable disclosed portfolio holdings include JPT Optoelectronics (688025.SH, laser/optical intelligent equipment), SZTKD Crystal Technology (603738.SH, quartz crystal resonators), BERTEL (603596.SH, automotive safety and ADAS), Xianglou New Materials (301160.SZ, precision stamping steel), Yuanzhuo Micro-Nano (LED, laser, DLP technology), and Huantian Tiancheng (silicon carbide epitaxial wafers). Portfolio maturation has been demonstrated through Nasdaq listings of Apollomics (via SPAC merger with Maxpro) and Miragene, plus A-share listings and pending IPO counseling filings.

The business model follows standard venture capital economics: revenue is generated through management fees charged against committed fund capital, supplemented by carried interest on successful exits. The firm does not sell a product, license technology, or operate a transactional marketplace. Distribution is conducted via direct enterprise sales of fund interests to limited partners, while deal sourcing is driven by a referral-based network of entrepreneurs, advisors, and an annual cycle of partner conferences and golf invitational events held across Chinese cities. In 2025 the firm extended its platform internationally via a strategic partnership with Abu Dhabi Capital to build a Middle East joint-venture platform for portfolio company Xiaoku Technology.

Name

South China Venture Capital

Legal name

中南创投基金

Website

https://scvc.cn

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

South China Venture Capital (中南创投基金) is a Shenzhen-based, privately held venture capital fund manager founded in 2008. It manages multiple RMB and USD funds, investing in early- and growth-stage startups in biomedicine, semiconductors, and artificial intelligence alongside scientist-entrepreneurs.

Ownership category

akta.pro rank

Product category

Venture Capital Fund Management

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital
• Private equity
• Fund management
• Early-stage investment
• Technology investment

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management: Manages multiple RMB and USD venture capital funds, generating returns through management fees and carried interest from successful portfolio exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

South China Venture Capital is a venture capital fund management firm that manages multiple RMB- and USD-denominated venture capital funds. It invests in early-stage and growth-stage technology companies in biotechnology and healthcare, semiconductors, and artificial intelligence, providing capital and strategic support to portfolio companies while delivering venture returns to its limited partners.

Product overview

South China Venture Capital (中南创投基金) is a venture capital fund management firm established in 2008, managing multiple RMB and USD venture capital funds. The firm operates as a fund-of-funds structure with two primary investment products: RMB-denominated venture capital funds and USD-denominated venture capital funds. These funds collectively focus on early-stage and growth-stage companies in biotechnology and healthcare, semiconductors, and artificial intelligence sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• RMB-denominated Venture Capital Fund (人民币创业投资基金)
• USD-denominated Venture Capital Fund (美元创业投资基金)

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Abu Dhabi Capital (阿布扎比资本)coreStrategic or Co-development Partner · 1 January 2025Strategic partnership with Abu Dhabi Capital to establish a significant joint venture platform in the Middle East for Xiaoku Technology (小库科技), indicating cross-border strategic collaboration.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Matrix Partners China: Early-stage China VC with focus on technology, healthcare, and consumer. Comparable given similar early-stage mandate and RMB-denominated fund structure serving Chinese LPs.
• ZhenFund: Early-stage China VC investing primarily in RMB with strong sector breadth across biotech, semis, and AI. Directly comparable given similar early-stage orientation and Chinese-domiciled fund structure.
• Source Code Capital: China-focused early/growth-stage VC investing across enterprise tech, biotech, and AI. Comparable given similar stage focus and RMB/USD fund presence.
• Zero2IPO Ventures: Beijing-based early-stage VC and sister vehicle to Zero2IPO Group. Comparable given Chinese early-stage mandate and similar sector breadth.
• Volcanics Venture: Shenzhen-based early-stage VC focused on enterprise, deep tech, and healthcare — overlapping heavily with SCVC's hard-tech and biotech mandate in the same geography.
• Northern Light Venture Capital: Beijing-based early-stage VC focused on TMT, biotech, and hard-tech. Highly comparable given similar early/growth-stage mandate and sector overlap in technology and healthcare.
• IDG Capital: One of China's longest-established early- and growth-stage tech VCs with both RMB and USD funds and a comparable focus on biotech, semiconductors, and enterprise tech. Direct peer given overlapping mandate, fund structure, and target sectors.

Broad incumbents

• HongShan (formerly Sequoia China): One of China's largest tech VCs/growth investors with broad exposure including AI and biotech. Larger incumbent covering all stages from seed to growth.
• Legend Capital: Established China-focused VC/growth investor with broader sector mandate but overlapping exposure to biotech and tech. Larger and more diversified than SCVC.
• Qiming Venture Partners: Shanghai-based VC with significant healthcare/biotech and tech exposure. Larger incumbent at similar stages to SCVC, with USD and RMB fund capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about South China Venture Capital